Key result
Tirzepatide improves waist circumference, HbA1c, and cuts triglycerides up to ~48% in obesity and prediabetes.
Why the study?
Does body weight reduction with tirzepatide improve cardiometabolic risk factors in adults with obesity and prediabetes?
RCT (n=458)
randomized
Does body weight reduction with tirzepatide improve cardiometabolic risk factors in adults with obesity and prediabetes?
In adults with obesity and prediabetes, tirzepatide treatment over 3 years is associated with improvements in cardiometabolic risk factors that are proportional to the magnitude of body weight reduction.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Findings in this analysis suggest that clinicians should target weight reductions greater than 10% to observe benefits in the lipid variables most relevant to atherosclerotic risk … and 5% or more to observe improvements in blood pressure and waist circumference. Benefits in hemoglobin A1C were already observed with less than 5% weight reduction.”
“In people with obesity with prediabetes treatment of the disease of obesity, treatment could achieve control of the disease, but not cure. Metabolic complications of obesity got better and stayed better. Functional complications of obesity got better and stayed better.”
“There was improvement in all cardiometabolic measures. Improvements in all domains of health-related quality of life. Off-drug weight regain was observed and was accompanied by worsening glycemia and increase in progression to type 2 diabetes.”
Greater weight loss with tirzepatide associated with larger cardiometabolic improvements; hypothesis-generating and should not yet change practice.
Background In the 3–year SURMOUNT–1 study, this post hoc analysis assessed changes in cardiometabolic risk factors based on body weight reduction thresholds with tirzepatide. Methods Participants (N=458) randomized to receive tirzepatide (pooled 5/10/15 mg doses) and with an on–treatment body weight measurement at Week 176 were included in the analysis. The proportion of participants achieving body weight reduction thresholds (‹5%, 5 to ‹10%, 10 to ‹15%, 15 to ‹20%, 20 to ‹25%, 25 to ‹30%, 30 to ‹35%, and ≥35%) at Week 176 and change from baseline at Week 176 in cardiometabolic risk factors, including blood pressure, lipid profile, and glycemic parameters, by body weight reduction thresholds were assessed. Results At baseline, mean waist circumference was 116.5 cm, systolic blood pressure: 126.1 mmHg, diastolic blood pressure: 80.4 mmHg, triglycerides: 8.5 mmol/L, HDL–C: 2.7 mmol/L, non–HDL–C: 7.9 mmol/L, LDL–C: 6.2 mmol/L, and HOMA–2–IR (computed with insulin): 2.1. Improvements in waist circumference (3.2–35.3 cm reduction), HbA1c (0.30–0.76% reduction) and triglycerides (15–48% reduction) were observed among all body weight reduction subgroups. HOMA2–IR, blood pressure and HDL–C, non–HDL–C and LDL–C also improved among participants who lost ≥5% of body weight. Overall, greater improvements in cardiometabolic risk factors were generally associated with greater body weight reduction. Conclusions In this post hoc analysis of the 3–year SURMOUNT–1 study, tirzepatide treatment was associated with improved cardiometabolic risk factors, that were generally greater in magnitude with higher degrees of body weight reduction among people with obesity and prediabetes.
No takes yet. Share an insight, caveat, or question.
Laffin et al. (2026) conducted an RCT in obesity and prediabetes (n=458). Tirzepatide was evaluated on changes in cardiometabolic risk factors based on body weight reduction thresholds at Week 176. Tirzepatide treatment in adults with obesity and prediabetes improved waist circumference (3.2-35.3 cm reduction), HbA1c (0.30-0.76% reduction), and triglycerides (15-48% reduction) at 176 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: